Abstract
Background-Albuminuria is an established risk marker for both cardiovascular and renal outcomes. Albuminuria can be reduced with drugs that block the renin-angiotensin system (RAS). We questioned whether the short-term drug-induced change in albuminuria would predict the long-term cardioprotective efficacy of RAS intervention. Methods and Results-We analyzed data from Reduction in Endpoints in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL), a double-blind, randomized trial in 1513 type 2 diabetic patients with nephropathy, focusing on the relationship between the prespecified cardiovascular end point (composite) or hospitalization for heart failure and baseline or reduction in albuminuria. Patients with high baseline albuminuria (≥3 g/g creatinine) had a 1.92-fold (95% CI, 1.54 to 2.38) higher risk for the cardiovascular end point and a 2.70-fold (95% CI, 1.94 to 3.75) higher risk for heart failure compared with patients with low albuminuria (
Original language | English |
---|---|
Pages (from-to) | 921-927 |
Number of pages | 7 |
Journal | Circulation |
Volume | 110 |
Issue number | 8 |
DOIs | |
Publication status | Published - Aug 24 2004 |
Keywords
- Albuminuria
- Angiotensin
- Cardiovascular disease
- Diabetes
- Proteinuria
ASJC Scopus subject areas
- Physiology
- Cardiology and Cardiovascular Medicine